

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E23/20 - Hormones 2

Deadline: 04.08.2020

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(193) Ferritin					7							7	6	86%
Samples and groups	[µg/L]													
Sample A		163	35	22	7							7	6	86%
Other					7	0						7		
							1x 4/1, 3x 4/60, 3x 4/179							
Sample B		364	80	22	7							7	6	86%
Other					7	0						7		
							1x 4/1, 3x 4/60, 3x 4/179							
(320) LH					7							7	7	100%
Samples and groups	[U/L]													
Sample A		9,93	2,3	24	7							7	7	100%
Other					7	0						7		
							1x 4/1, 3x 4/12, 3x 4/60							
Sample B		13,5	3,1	23	7							7	7	100%
Other					7	0						7		
							1x 4/1, 3x 4/12, 3x 4/60							
(321) FSH					7							7	7	100%
Samples and groups	[U/L]													
Sample A		5,42	0,38	7,0	7							7	7	100%
Other					7	0						7		
							1x 4/1, 3x 4/12, 3x 4/60							
Sample B		9,72	0,44	4,5	7							7	7	100%
Other					7	0						7		
							1x 4/1, 3x 4/12, 3x 4/60							
(322) Prolactin					7							7	7	100%
Samples and groups	[mU/L]													
Sample A		312	69	22	7							7	7	100%
Other					7	0						7		
							1x 4/1, 2x 4/12, 2x 4/60, 2x 4/179							
Sample B		719	130	19	7							7	7	100%
Other					7	0						7		
							1x 4/1, 2x 4/12, 2x 4/60, 2x 4/179							
(325) Insulin					5							5	5	100%
Samples and groups	[mU/L]													
Sample A		38,3	6,3	17	5							5	5	100%
Other					5	0						5		
							1x 4/1, 1x 4/12, 1x 4/60, 2x 4/179							
Sample B		94,4	12	13	5							5	5	100%
Other					5	0						5		
							1x 4/1, 1x 4/12, 1x 4/60, 2x 4/179							
(326) Folate					9							9	8	89%
Samples and groups	[nmol/L]													
Sample A		10,3	1,5	15	9							9	8	89%
Other					9	0						9		
							2x 4/1, 1x 4/12, 4x 4/60, 2x 4/179							
Sample B		31,1	2,9	9,4	9							9	8	89%
Other					9	0						9		
							2x 4/1, 1x 4/12, 4x 4/60, 2x 4/179							
(327) Vitamin B12					9							9	8	89%
Samples and groups	[pmol/L]													
Sample A		255	20	7,9	9							9	8	89%
Other					9	0						9		
							2x 4/1, 1x 4/12, 4x 4/60, 2x 4/179							
Sample B		652	33	5,0	9							9	9	100%
Other					9	0						9		
							2x 4/1, 1x 4/12, 4x 4/60, 2x 4/179							
(328) hGH					2							2	2	100%
Samples and groups	[mU/L]													
Sample A		14,0	1,1	7,9	2							2	2	100%
Other					2	0						2		
							1x 4/29, 1x 4/60							
Sample B		26,6	1,8	6,8	2							2	2	100%
Other					2	0						2		
							1x 4/29, 1x 4/60							

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E23/20 - Hormones 2

Deadline: 04.08.2020

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(329) IGF-1					2							2	2	100%
Samples and groups	[µg/L]													
Sample A		590	210	36	2							2	2	100%
Other					2	0						2		
							1x 4/29, 1x 4/60							
Sample B		349	73	21	2							2	2	100%
Other					2	0						2		
							1x 4/29, 1x 4/60							
(390) Renin					2							2	2	100%
Samples and groups	[ng/L]													
Sample A		38,3	1,7	4,5	2							2	2	100%
Other					2	0						2		
							2x 4/164							
Sample B		38,7	1,5	3,8	2							2	2	100%
Other					2	0						2		
							2x 4/164							
(392) IGF-BP3					1							1	1	100%
Samples and groups	[µg/L]													
Sample A		3300			1							1	1	100%
Other					1	0						1		
							1x 4/60							
Sample B		3370			1							1	1	100%
Other					1	0						1		
							1x 4/60							
(393) C-peptide					7							7	7	100%
Samples and groups	[pmol/L]													
Sample A		252	100	40	7							7	7	100%
Other					7	0						7		
							2x 4/1, 3x 4/60, 2x 4/179							
Sample B		257	94	37	7							7	7	100%
Other					7	0						7		
							2x 4/1, 3x 4/60, 2x 4/179							
(394) SHBG					5							5	4	80%
Samples and groups	[nmol/L]													
Sample A		30,4	0,93	3,1	5							5	4	80%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		30,4	0,93	3,1	5	0	CVPG	30,2	0,27	20%	24,1	36,3	5	
(60) Roche														
Sample B		29,6	1,5	5,1	5							5	5	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		29,6	1,5	5,1	5	0	CVPG	30,2	0,28	20%	24,1	36,3	5	
(60) Roche														
(405) Parathyroid hormone (PTH)					7							7	6	86%
Samples and groups	[pmol/L]													
Sample A		19,1	2,4	13	7							7	6	86%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		18,6	1,8	9,4	6	0	CVPG	19,5	0,21	23%	15	24	6	
(60) Roche														
Other					1	0						1		
							1x 4/12							
Sample B		10,3	1,6	15	7							7	6	86%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		10,1	1,2	12	6	0	CVPG	10,4	0,11	23%	8	12,8	6	
(60) Roche														
Other					1	0						1		
							1x 4/12							

st_kn_p

End of report

Printed: 17.08.2020